The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
Minimum 18 years of age
Written informed consent
Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease
Former desaturation under exercise defined as SpO2-decrease >3%
Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 < 6.9 kPa
Inability or contraindications to undergo the investigated intervention
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.
Crossover
6-minute walk distance (6MWD) test on ambient conditions
Other intervention6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
6-minute walk distance (6MWD) test with supplemental oxygen (LOX)
Other intervention6-minute walk test(6MWT) test will be performed according to clinical standards with supplemental liquid oxygen therapy (LOX, approximately 4l/min, nasal)
6-minute walk distance (6MWD) with supplemental oxygen therapy (SOT) vs. ambient air
Change in 6MWD in meter between supplemental liquid oxygen therapy (LOX) via nasal cannula vs. ambient air
SpO2 at rest and peak 6MWD with supplemental liquid oxygen therapy (LOX) vs. ambient air
Change of the arterial oxygen saturation by pulse oximeter (SpO2) at rest and at peak 6MWD with LOX approximately 4l /min vs. ambient air
Heart rate at rest and peak 6MWD with supplemental liquid oxygen therapy (LOX) vs. ambient air
Change of heart rate (bpm) at rest and at peak 6MWD with LOX vs. ambient air
Borg dyspnea at rest and peak 6MWT with supplemental liquid oxygen therapy (LOX) s. ambient air
Change of Borg dyspnea scale (CR10, 0-10 where 10 is the worst dyspnea) at rest and at peak 6MWD with LOX vs. ambient air
Borg leg fatigue scale at rest and peak 6MWD with supplemental liquid oxygen therapy (LOX) vs. ambient air
Change of Borg leg fatigue scale (CR10, 0-10 where 10 is the strongest led fatugue) at rest and at peak 6MWT with LOX vs. ambient air
Click on the lead sponsor to view all of their trials.
Silvia Ulrich Somaini
Lead sponsor
University of Zurich
Sponsor institution
